Document is current
Any future updates will be listed below
-
Authors
Labauge, Pierre
Créange, Alain
Moreau, Thibault
Nouvet-Gire, Jocelyne
Pedespan, Bernard
Heinzlef, Olivier
Texier, Nathalie
Gros, Marilyn
Marti, Catherine
Ruiz, Marta https://orcid.org/0009-0007-7744-4207
Martinez, Mikel
Castelnovo, Giovanni
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04221191 at ClinicalTrials.govDocuments that mention this clinical trial
TEC-ADHERE: Real-World Persistence and Adherence on Dimethyl Fumarate in Patients with Relapsing–Remitting Multiple Sclerosis in the French OroSEP Patient-Support Program
https://doi.org/10.1007/s40120-024-00674-x
-
Funding
Funding for this research was provided by:
Biogen France SAS
- License Information
-
More Information
Article History
Received: 26 June 2024
Accepted: 14 October 2024
First Online: 11 November 2024
Declarations
:
: Pierre Labauge has received financial support for participation in conferences and laboratory fees from Biogen, Bristol Myers Squibb, Merck, Novartis, Sanofi Genzyme, and Teva. Alain Créange has received financial support for research from Biogen, GeNeuro, MedDay, Novartis, Octapharma, and Roche and has received honoraria from Biogen, GeNeuro, Novartis, and Roche. Thibault Moreau has received research support and scientific consultant fees from Biogen, Merck, Novartis, Roche, and Sanofi. Jocelyne Nouvet-Gire, Nathalie Texier, and Mikel Martinez have no conflicts of interest to disclose. Bernard Pedespan has received scientific consultant fees from AbbVie, Angelini, Eli Lilly and Company, Merck, Novartis, and Sanofi. Olivier Heinzlef has received consulting and lecture fees from Almirall, Bayer Schering, Biogen, Genzyme, Merck, Novartis, and Teva, travel grants from Biogen, Genzyme, Merck Serono, Novartis, and Teva, and research support from Merck, Novartis, and Roche. Marilyn Gros and Marta Ruiz are employees of and may own stock in Biogen. Catherine Marti was an employee of and may have owned stock in Biogen at the time that the study was conducted and is currently an employee of LifeScan France SAS. Giovanni Castelnovo has received financial support for participation in conferences and laboratory fees from AbbVie, Biogen, Bristol Myers Squibb, Janssen, Merck, Merz, Novartis, Roche, Sanofi Genzyme, and Teva.
: This study was conducted in accordance with the International Council for Harmonisation guidelines, the ethical principles outlined in the Declaration of Helsinki and/or, where applicable, the European Directive 2001/20 in relation to Good Clinical Practice. The study was submitted to and approved by a French Committee for the Protection of Persons (Comité de Protection des Personnes) on July 11, 2019. All patients provided oral informed consent at M0 regarding TEC-ADHERE and authorization to use protected health information. For OroSEP, patients provided written consent to participate in the PSP at DMF initiation.
